Diagnostics Are Warming Up in Era of Fast, Cheap Sequencing
Xconomy interviewed Mohr Davidow's Rowan Chapman at the J.P. Morgan conference. This piece runs on the same day Rowan will be a speaker at the Xconomy hosted event, Computing in the Age of the $1,000 Genome
Quite a few players in the movement toward super-fast, super-cheap gene sequencing see a mix of arcane science, breathless hype, and modest results. Despite a decade of talk about personalized medicine, nobody walks into a doctors’ office today and gets a universal test that can predict their medical future or give advice on how to avoid nasty diseases.
Yet when Rowan Chapman looks around today, she sees the next-generation of DNA sequencing as paving the way for specific diagnostic tests that would have been impossible to imagine before. And each of them can generate hundreds of millions a year in revenue in the not-so distant future.
“You’re going to see a lot of diagnostic applications enabled by next-gen sequencing,” Chapman says. “Without the throughput we have today, it would have been impossible, really cost prohibitive.”